Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRY812 in LIV-1 Positive Advanced Gynecologic Malignancies
NCT07311538Phase 2Not yet recruiting
- Sponsor
- BioRay Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
01
Overview
A Phase 2 trial of BRY812 in ovarian cancer, endometrial cancer (EC), ovarian clear cell carcinoma (OCCC), sponsored by BioRay Pharmaceutical. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
BRY812
03
Conditions
ovarian cancerendometrial cancer (EC)ovarian clear cell carcinoma (OCCC)
Beyond the preview
Go deeper on NCT07311538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07311538.